FDA Approves Trikafta for Cystic Fibrosis Patients!

Fantastic news came from the Food and Drug Administration (FDA) in recent weeks! A medication created by Vertex Pharmaceuticals called Trikafta was approved through the FDA 5 months ahead of schedule for Cystic Fibrosis (CF). The news of this drug impacts 90% of the cf community. Trikafta is not like anything that has been produced before.

"Trikafta is (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation." "Cystic fibrosis is caused by a defective protein that results from mutations in the CFTR gene. While there are approximately 2,000 known mutations of the CFTR gene, the most common mutation is the F508del mutation." "Trikafta is a combination of three drugs that target the defective CFTR protein. It helps the protein made by the CFTR gene mutation function more effectively. "

Trikafta is not a cure, but it will help make the symptoms and treatments more manageable. This very promising in changing the direction of the patient's lives.

In January of 2019, Andrea and I were able to tour Vertex Pharmaceuticals and speak to their marketing team. It was an eye-opening experience to meet several scientists and see the process that goes into making such a complex medication. We are grateful for the hours spent with test tubes, chemicals, and countless days spent on trial and error. 

Our family has been both very shocked and very excited upon hearing this news. Right now, Andrea and I are eligible for this medication and will be starting it any time soon. This will not only add years to our lives but increase our quality of life. We are very fortunate to be able to be on a drug that changes our lives in a matter of doses.

Here is the link to the FDA's article!
https://www.fda.gov/news-events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis